These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 6978548)

  • 1. Protection of platelet surface bound factors IXa and VIII against specific inhibitors.
    Váradi K; Elödi S
    Thromb Haemost; 1982 Feb; 47(1):32-5. PubMed ID: 6978548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The second epidermal growth factor-like domain of human factor IXa mediates factor IXa binding to platelets and assembly of the factor X activating complex.
    Wong MY; Gurr JA; Walsh PN
    Biochemistry; 1999 Jul; 38(28):8948-60. PubMed ID: 10413468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor X bound to the surface of activated human platelets is preferentially activated by platelet-bound factor IXa.
    Scandura JM; Walsh PN
    Biochemistry; 1996 Jul; 35(27):8903-13. PubMed ID: 8688426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coagulation factor IX residues G4-Q11 mediate its interaction with a shared factor IX/IXa binding site on activated platelets but not the assembly of the functional factor X activating complex.
    Ahmad SS; Wong MY; Rawala R; Jameson BA; Walsh PN
    Biochemistry; 1998 Feb; 37(6):1671-9. PubMed ID: 9484238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of activated factors II, VII, IX, and X by synthetic organic compounds directed against the active-site seryl residue.
    Van der Woerd-de Lange JA; van Dam-Mieras MC; Hemker HC
    Haemostasis; 1981; 10(6):315-47. PubMed ID: 6976920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of antithrombin III on the activity of the coagulation factors VII, IX and X.
    Osterud B; Miller-Andersson M; Abildgaard U; Prydz H
    Thromb Haemost; 1976 Apr; 35(2):295-304. PubMed ID: 61631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heparin inhibits the intrinsic tenase complex by interacting with an exosite on factor IXa.
    Sheehan JP; Kobbervig CE; Kirkpatrick HM
    Biochemistry; 2003 Sep; 42(38):11316-25. PubMed ID: 14503882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithrombin-mediated inhibition of factor VIIa-tissue factor complex by the synthetic pentasaccharide representing the heparin binding site to antithrombin.
    Lormeau JC; Herault JP; Herbert JM
    Thromb Haemost; 1996 Jul; 76(1):5-8. PubMed ID: 8819242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protamine inhibits formation of the covalent factor IXa-anti-thrombin complex.
    Brecher AS; Roland AR
    Blood Coagul Fibrinolysis; 2008 Sep; 19(6):591-6. PubMed ID: 18685444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor IX of the blood coagulation system: a review.
    Taran LD
    Biochemistry (Mosc); 1997 Jul; 62(7):685-93. PubMed ID: 9331959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics of formation of factor IXa-factor VIII complex on the surface of platelets.
    Elödi S; Váradi K; Vörös E
    Thromb Res; 1981 Mar; 21(6):695-700. PubMed ID: 6791301
    [No Abstract]   [Full Text] [Related]  

  • 12. Use of phage display for the generation of human antibodies that neutralize factor IXa function.
    Suggett S; Kirchhofer D; Hass P; Lipari T; Moran P; Nagel M; Judice K; Schroeder K; Tom J; Lowman H; Adams C; Eaton D; Devaux B
    Blood Coagul Fibrinolysis; 2000 Jan; 11(1):27-42. PubMed ID: 10691097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Annexin V inhibition of factor IXa-catalyzed factor X activation on human platelets and on negatively-charged phospholipid vesicles.
    London F; Ahmad SS; Walsh PN
    Biochemistry; 1996 Dec; 35(51):16886-97. PubMed ID: 8988028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A binding site expressed on the surface of activated human platelets is shared by factor X and prothrombin.
    Scandura JM; Ahmad SS; Walsh PN
    Biochemistry; 1996 Jul; 35(27):8890-902. PubMed ID: 8688425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apparent intrinsic prothrombinase activity of human Factor X zymogen: identification with Factor VIII inhibitor bypassing activity (FEIBA).
    Estry DW; Tishkoff GH
    Thromb Res; 1984 Dec; 36(6):549-62. PubMed ID: 6335607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The multiple levels of endothelial cell-coagulation factor interactions.
    Nawroth PP; Handley D; Stern DM
    Clin Haematol; 1986 May; 15(2):293-321. PubMed ID: 3524930
    [No Abstract]   [Full Text] [Related]  

  • 17. Cleavage and inactivation of Factor IX by granulocyte elastase.
    Takaki A; Enfield DL; Thompson AR
    J Clin Invest; 1983 Nov; 72(5):1706-15. PubMed ID: 6605369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High molecular weight kininogen protects human plasma kallikrein and factor XIa against inactivation by plasma protease inhibitors.
    Schapira M; Scott CF; Colman RW
    Trans Assoc Am Physicians; 1981; 94():190-7. PubMed ID: 6979819
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of granulocyte proteases on human coagulation factors IX and X. The protective effect of calcium.
    Kárpáti J; Váradi K; Elödi S
    Hoppe Seylers Z Physiol Chem; 1982 May; 363(5):521-5. PubMed ID: 7047353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrinsic procoagulant surface induced by hypercholesterolaemia on rabbit aortic endothelium.
    Lupu F; Moldovan N; Ryan J; Stern D; Simionescu N
    Blood Coagul Fibrinolysis; 1993 Oct; 4(5):743-52. PubMed ID: 8292724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.